# HER2CLIMB-05 (NCT05132582)

> A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05132582
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: HER2 Positive Breast Cancer
- Interventions: Tucatinib; Trastuzumab; Pertuzumab; Combination product: Trastuzumab + Pertuzumab; Placebo
- Enrollment: 654
- Primary outcome: Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

## Commentary we found

- X threads: 83
- Podcasts: 31
- YouTube: 30
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=her2climb-05-nct05132582

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05132582", "email": "<work email>"}; the inbox owner confirms by the emailed link.